RBC Capital downgrades Kymera Therapeutics to Sector Perform

0 min read     Updated on 13 Jul 2026, 09:50 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics from Outperform to Sector Perform and raised the price target to $115 from $106.

powered bylight_fuzz_icon
45505217

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics from Outperform to Sector Perform and raised the price target to $115 from $106. The adjustment reflects a revised outlook on the stock despite the increased valuation target.

Rating and Price Target Changes

The downgrade moves the stock's rating from Outperform to Sector Perform. Simultaneously, the price target was increased, indicating a revised expectation for the stock's performance.

Metric Previous Value New Value
Rating Outperform Sector Perform
Price Target $106 $115

What specific factors led to the downgrade despite the raised price target?

How might this rating change influence investor sentiment towards Kymera Therapeutics?

What are the potential risks or opportunities that could impact the stock's future performance?

like17
dislike

B of A, Truist raise Kymera Therapeutics price targets

0 min read     Updated on 30 Jun 2026, 10:56 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

B of A Securities maintained a Buy rating on Kymera Therapeutics and increased its price target to $125. This follows target hikes by Truist Securities to $136 and B. Riley Securities to $155, alongside a Buy rating from Canaccord Genuity.

powered bylight_fuzz_icon
43954883

*this image is generated using AI for illustrative purposes only.

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating for Kymera Therapeutics and raised the price target from $110 to $125. This adjustment follows similar moves by Truist Securities and B. Riley Securities, reflecting updated valuation outlooks for the biopharmaceutical company.

Kymera Therapeutics trades on the NASDAQ under the ticker symbol KYMR. The endorsements from these firms signal confidence in the stock's trajectory despite shifting price objectives among analysts.

Firm Analyst Rating Previous Target New Target
B of A Securities Tazeen Ahmad Buy $110 $125
B. Riley Securities Kalpit Patel Buy $117 $155
Canaccord Genuity Edward Nash Buy $106 $129
Truist Securities Srikripa Devarakonda Buy $116 $136

What specific clinical milestones or data releases are expected to drive Kymera's valuation in the coming quarters?

How might the divergence in price targets among analysts, such as B. Riley's $155 versus B of A's $125, reflect differing views on the company's pipeline potential?

What impact could these analyst upgrades have on institutional investor sentiment and trading volume for KYMR in the near term?

like19
dislike

More News on Kymera Therapeutics Inc